Anavex Life Sciences Corp (AVXL)

[falconer66a]

CTAD Announces CTAD

This morning the University of California – San Francisco made an announcement of its CTAD conference; the event where Anavex will be making a presentation on its clinical study of blarcamesine treating Alzheimer’s.

Interestingly, not a word about the Anavex presentation. The announcement stated, “The CTAD conference will feature top neurologists, clinicians and memory loss researchers, coming from as far afield as Stockholm and Seoul, to demonstrate new findings and initiatives in the diagnosis and treatment of Alzheimer’s disease, the most common type of dementia afflicting an estimated 6.5 million Americans. The conference, which is sold out for in-person attendance, will run from Nov. 29 to Dec. 2.”

Further, “President of the CTAD22 Scientific Committee, Michael Weiner, MD, professor of radiology, medicine and neurology at UCSF, noted that it has only been 15 years since imaging techniques have enabled Alzheimer’s disease to be identified in living people. “Now amyloid PET is widely available, tau PET is being employed by many clinical trials, and, very recently, blood tests for Alzheimer’s disease have shown great promise for screening and even diagnosis.”

Weiner said that he expects many attendees to be drawn to presentations on anti-amyloid therapies, especially lecanemab and donanemab, which have shown promising results. “There is growing evidence that some of these therapies appear to slow cognitive decline. Unfortunately, these treatments are also associated with abnormal differences seen in imaging, including brain swelling and bleeding in the brain,” he said. “There is considerable controversy concerning the significance and impact of these findings, including whether or not governments and medical insurance will provide financial coverage for such treatments.”

Still, with Alzheimer's professionals, everything stuck in the tau and amyloid motifs. Dr. Missling’s presentation will be a bit off-topic, trying to fix or prevent Alzheimer’s by activating, of all things, the sigma-1 receptor. Except for the few who might be following Anavex science, most of the conference audience may have never heard of the sigma-1 receptor; or understand in any way that its proper activation could somehow stop or reverse the progression of Alzheimer’s symptoms.

https://www.eurekalert.org/news-releases/972627